Pfizer Files Lawsuit in Australia to Halt Sales of BRENZYS (etanercept)

Goodwin
Contact

Goodwin

Last week Pfizer filed a lawsuit in a federal court of Australia against respondents Samsung Bioepis, Merck, Sharp & Dohme, Organon, and Arrow, to halt sales of their biosimilar BRENZYS (etanercept).  Pfizer alleges that the respondents infringe Australian Patent No. 2005280034, titled “Production of polypeptides,” with claims directed to cell culture methods.  BRENZYS is a biosimilar to ENBREL (etanercept), and was approved by Australia’s Therapeutic Goods Administration in 2016.  Pfizer is seeking damages from sales of BRENZYS in Australia, and a court order barring the sale of the drug until Pfizer’s patent expires.

Stay tuned to Big Molecule Watch for further developments on this case.

[View source.]

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide